A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial-stage medical technology company dedicated to transforming the lives of patients suffering from fluid overload through science, collaboration, and innovative technology. The company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow® and the Aquadex SmartFlow® systems (collectively the “Aquadex System”). The Aquadex SmartFlow® system is indicated for temporary (up to eight hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. Please note that selected authors in the citations below are either current consultants to the Company or were previously compensated consultants.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 8.2M | 8.7M | 8.9M | 8.5M | 7.9M | - |
| Net Income | -17M | -11M | - | - | - | -16M |
| EPS | $236.85 | $-353.22 | $-15,122.52 | $-122,818.50 | $-419,479.20 | $-1,568,490.00 |
| Free Cash Flow | -9.4M | -9.7M | -18M | -15M | -18M | -17M |
| ROIC | -109.3% | -133.0% | - | - | - | -96.7% |
| Gross Margin | 59.1% | 64.9% | 56.2% | 55.7% | 56.7% | - |
| Debt/Equity | 0.00 | 0.51 | 0.00 | 0.00 | 0.00 | 0.01 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -11M | -11M | -18M | -17M | -20M | -17M |
| Operating Margin | -135.3% | -125.7% | -198.9% | -201.0% | -246.5% | - |
| ROE | -423.8% | -223.2% | - | - | - | -97.0% |
| Shares Outstanding | 2M | 0M | 0M | 0M | 0M | 0M |
Nuwellis, Inc. passes 1 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 58.4%.
Nuwellis, Inc. (NUWE) has a 5-year average return on invested capital (ROIC) of -114.8%. This is below average and may indicate limited pricing power.
Nuwellis, Inc. (NUWE) has a market capitalization of $2M. It is classified as a small-cap stock.
Nuwellis, Inc. (NUWE) does not currently pay a regular dividend.
Nuwellis, Inc. (NUWE) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
Nuwellis, Inc. (NUWE) reported annual revenue of $9 million in its most recent fiscal year, based on SEC EDGAR filings.
Nuwellis, Inc. (NUWE) has a net profit margin of -121.6%. The company is currently unprofitable.
Nuwellis, Inc. (NUWE) generated $-10 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Nuwellis, Inc. (NUWE) has a debt-to-equity ratio of 0.51. This indicates moderate leverage.
Nuwellis, Inc. (NUWE) reported earnings per share (EPS) of $-353.22 in its most recent fiscal year.
Nuwellis, Inc. (NUWE) has a return on equity (ROE) of -223.2%. A negative ROE may indicate losses or negative equity.
Nuwellis, Inc. (NUWE) has a 5-year average gross margin of 58.4%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for Nuwellis, Inc. (NUWE), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Nuwellis, Inc. (NUWE) has a book value per share of $62.68, based on its most recent annual SEC filing.
No recent press releases.